Periodic Fever Syndrome Market Share, Size, Trends, Industry Analysis Report, By Indication (Hyperimmuno-globulinemia D Syndrome (HIDS), Familial Mediterranean Fever (FMF), TNF Receptor-Associated Periodic Syndrome (TRAPS), Cryopyrin-Associated Periodic S

Periodic Fever Syndrome Market Share, Size, Trends, Industry Analysis Report, By Indication (Hyperimmuno-globulinemia D Syndrome (HIDS), Familial Mediterranean Fever (FMF), TNF Receptor-Associated Periodic Syndrome (TRAPS), Cryopyrin-Associated Periodic Syndrome (CAPS) Others); By Treatment; By End-Use; By Region; Segment Forecast, 2024 - 2032

The global periodic fever syndrome market size is expected to reach USD 881.95 million by 2032, according to a new study by Polaris Market Research. The report “Periodic fever syndrome Market Share, Size, Trends, Industry Analysis Report, By Indication (Hyper-immunoglobulinemia D syndrome, Familial Mediterranean Fever, TNF Receptor Associated periodic syndrome, Cryopyrin Associated periodic syndrome, Others); By Treatment; By End-Use; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rise of the sector is being aided by a rise in government programs focused on raising public knowledge of uncommon disorders. Increased research activity and quick technical breakthroughs are resulting in the creation of new medications, enhanced diagnostic capabilities, and treatments, all of which contribute significantly to market growth. The sector is likely to benefit from new medication approvals to treat the condition.

FMF is the most prevalent monogenic autoinflammatory illness in the world and in Canada, with repeated, self-limited bouts of fever and inflammation involving serous and synovial membranes. It is inherited in an autosomal recessive manner, and its incidence is highest among groups of Middle Eastern and Mediterranean ancestry, with varying prevalence in other ethnicities.

Cryopyrin-associated periodic syndrome (CAPS) is a series of autoinflammatory illnesses that are connected. Mutations in the CIASl gene, which encodes cryopyrin, induce the enhanced activity of interleukin I and other cytokines, which activate their target cells via an intracellular receptor known as the Toll-like receptor or nucleotide oligomerization domain protein ligation.

Ilaris is the first and only FDA-approved biologic therapy for TRAPS, Hyper immunoglobulin D Syndrome, & Familial Mediterranean Fever. All three disorders are part of a rare category of auto-inflammatory diseases known as Periodic Fever Syndromes. FMF is the most frequent condition, affecting primarily those of Eastern Mediterranean heritage. It affects 1 in 250 to 1 in 1,000 people in various populations, with a majority of them being children.

Commonly used medications, such as hydroxychloroquine, have seen a huge increase in demand for COVID-19 control. Because of the need for vaccinations and treatment medications for COVID-19, the biopharma industry is likely to increase significantly in the future. This, in turn, is projected to have a major influence on the market for periodic fever syndrome. Recently, Canakinumab has been licensed for the treatment of individuals with periodic fever syndrome, cryopyrin-associated periodic syndrome, periodic fever syndrome, and systemic juvenile systemic arthritis which likely boosts the growth of periodic fever syndrome business.

Periodic Fever Syndrome Market Report Highlights

Oral anti-inflammatory medicines such as corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs), among others, are expected to hold a significant market share over the projection period as these are used to treat periodic fever syndrome.

North America is a market leader in the worldwide periodic fever syndrome sector due to the expanding penetration of the region's key companies and the increased emphasis on patient care and monitoring.

The global players include Merck & Co Inc, Simvastatin, Swedish Orphan Biovitrum AB, and Novartis AG.

Polaris Market Research has segmented the periodic fever syndrome market report based on indication, treatment, end-use and region:

Periodic Fever Syndrome, Indication Outlook (Revenue - USD Million, 2019 - 2032)

Hyperimmunoglobulinemia D syndrome

Familial Mediterranean Fever (FMF)

TNF Receptor Associated Periodic Syndrome (TRAPS)

Cryopyrin Associated Periodic Syndrome

Others

Periodic Fever Syndrome, Treatment Outlook (Revenue - USD Million, 2019 - 2032)

Oral anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs (NSAIDs)

Anti-TNF therapy

Statins

Others

Periodic fever syndrome, End-Use Outlook (Revenue - USD Million, 2019 - 2032)

Hospitals

Retail Pharmacy

Periodic fever syndrome, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa